A New Humanized Mouse Model Mimics Humans in Lacking α-Gal Epitopes and Secreting Anti-Gal Antibodies
Overview
Authors
Affiliations
Mice have been used as accepted tools for investigating complex human diseases and new drug therapies because of their shared genetics and anatomical characteristics with humans. However, the tissues in mice are different from humans in that human cells have a natural mutation in the α1,3 galactosyltransferase (α1,3GT) gene and lack α-Gal epitopes on glycosylated proteins, whereas mice and other nonprimate mammals express this epitope. The lack of α-Gal epitopes in humans results in the loss of immune tolerance to this epitope and production of abundant natural anti-Gal Abs. These natural anti-Gal Abs can be used as an adjuvant to enhance processing of vaccine epitopes to APCs. However, wild-type mice and all existing humanized mouse models cannot be used to test the efficacy of vaccines expressing α-Gal epitopes because they express α-Gal epitopes and lack anti-Gal Abs. Therefore, in an effort to bridge the gap between the mouse models and humans, we developed a new humanized mouse model that mimics humans in that it lacks α-Gal epitopes and secretes human anti-Gal Abs. The new humanized mouse model (Hu-NSG/α-Gal) is designed to be used for preclinical evaluations of viral and tumor vaccines based on α-Gal epitopes, human-specific immune responses, xenotransplantation studies, and in vivo biomaterials evaluation. To our knowledge, our new Hu-NSG/α-Gal is the first available humanized mouse model with such features.
Park H, Lee E, You Y, Rhee M, Kim J, Hwang S J Diabetes Investig. 2024; 15(6):693-703.
PMID: 38634411 PMC: 11143419. DOI: 10.1111/jdi.14216.
N-Glycosylation as a Modulator of Protein Conformation and Assembly in Disease.
Pasala C, Sharma S, Roychowdhury T, Moroni E, Colombo G, Chiosis G Biomolecules. 2024; 14(3).
PMID: 38540703 PMC: 10968129. DOI: 10.3390/biom14030282.
Modulating antibody effector functions by Fc glycoengineering.
Garcia-Alija M, Van Moer B, Sastre D, Azzam T, Du J, Trastoy B Biotechnol Adv. 2023; 67:108201.
PMID: 37336296 PMC: 11027751. DOI: 10.1016/j.biotechadv.2023.108201.
Bamgbose T, Alberdi P, Abdullahi I, Inabo H, Bello M, Sinha S Sci Rep. 2022; 12(1):7484.
PMID: 35524154 PMC: 9075922. DOI: 10.1038/s41598-022-11632-8.
Altered glycosylation in pancreatic cancer and beyond.
Lumibao J, Tremblay J, Hsu J, Engle D J Exp Med. 2022; 219(6).
PMID: 35522218 PMC: 9086500. DOI: 10.1084/jem.20211505.